BOSTON and CHESTERFIELD, Mo., Sept. 24, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced its new partnership with NOVUS International, an innovator and leader in intelligent nutrition, to develop advanced feed additives designed to meet the evolving needs of the animal agriculture industry. By utilizing Ginkgo Enzyme Services, NOVUS will work with Ginkgo to build more efficient enzymes that can be produced cost-effectively.

With the agricultural sector facing heightened volatility, including rising feed costs and tightening margins, NOVUS is committed to supporting its customers by optimizing the health and performance of livestock. This partnership aims to bring cutting-edge technologies to market, enhancing the sustainability and efficiency of animal production systems. These innovations are intended to improve the overall well-being of chickens, pigs, and cows, thereby supporting producers in delivering nutritious and affordable animal products to consumers.

Abishek Shingote, Associate VP of Global Strategic Marketing, Technology, and Innovation at NOVUS, highlighted the partnership's potential: "With the challenges and volatility facing the agriculture industry, a multifactorial approach is needed for producers to meet their financial goals and end customers to continue to enjoy nutritious and affordable meat, milk, and eggs. This multifactorial approach requires advanced technologies combined with application knowledge. The partnership with Ginkgo Bioworks puts NOVUS on the path to create innovative technologies that support health and performance consistency in chickens, pigs, and cows. The products we're working to develop came out of conversation with NOVUS customers and deep analysis of industry needs. Innovation is at the heart of NOVUS. Sustaining thriving livestock is a challenge, especially against economic, environmental and regulatory headwinds. We make it our mission to find new and novel ways to support our stakeholders and the industry."

Dan Rosmarin, VP, Commercial, at Ginkgo Bioworks: "Partnering with NOVUS presents an exciting opportunity to apply Ginkgo's enzyme development services in a very important domain. Together, we can accelerate the development of innovative products that offer tangible benefits to the animal agriculture industry, with the potential to enhance both productivity and sustainability. This partnership will leverage Ginkgo's research innovation platform combined with NOVUS's animal feed application knowledge, putting us on the path to create innovative technologies that meet the evolving needs of the livestock industry. We are very excited to see scientific progress already made on this project at Ginkgo and appreciate the opportunity to contribute to NOVUS's next generation of innovative feed additives."

To learn more about how you can bring innovative biological solutions to life, read more at Ginkgo Enzyme Services.

About Ginkgo Bioworks
Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo Biosecurity is building and deploying the next-generation infrastructure and technologies that global leaders need to predict, detect, and respond to a wide variety of biological threats. For more information, visit ginkgobioworks.com and ginkgobiosecurity.com, read our blog, or follow us on social media channels such as X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn.

GINKGO BIOWORKS INVESTOR CONTACT:
This email address is being protected from spambots. You need JavaScript enabled to view it.

GINKGO BIOWORKS MEDIA CONTACT:
This email address is being protected from spambots. You need JavaScript enabled to view it.

About NOVUS
NOVUS is the intelligent nutrition company providing solutions for the animal agriculture industry around the world. The company's portfolio includes trace minerals, nutritional enzymes, feed digestibility and meat quality solutions, and methionine supplementation products, as well as a network of experts globally who provide guidance on management best practices. To learn how NOVUS is Made of More™, visit novusint.com.

NOVUS MEDIA CONTACT
This email address is being protected from spambots. You need JavaScript enabled to view it.

Forward-Looking Statements of Ginkgo Bioworks
This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the capabilities and potential success of the partnership and Ginkgo's cell programming platform. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (ii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (v) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vi) the outcome of any pending or potential legal proceedings against Ginkgo, (vii) our ability to realize the expected benefits from and the success of our Foundry platform programs, (viii) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, and (ix) the product development or commercialization success of our customers. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on February 29, 2024, Ginkgo's most recent quarterly report on Form 10-Q, and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations.